Takeda Pharmaceutical Co Ltd
TSE:4502
Intrinsic Value
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. [ Read More ]
The intrinsic value of one
Takeda Pharmaceutical Co Ltd
stock under the Base Case scenario is
5 133.2
JPY.
Compared to the current market price of 4 069 JPY,
Takeda Pharmaceutical Co Ltd
is
Undervalued by 21%.
Takeda Pharmaceutical Co Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Takeda Pharmaceutical Co Ltd's market capitalization is 6.4T JPY.
Takeda Pharmaceutical Co Ltd stock price is 4 069 JPY.
Takeda Pharmaceutical Co Ltd stock price (4069 JPY) is 21% less than its Intrinsic Value (5 133.2 JPY).
Takeda Pharmaceutical Co Ltd stock price (4069 JPY) is 3% less than its DCF Value (4 203.03 JPY). Open DCF Valuation
Takeda Pharmaceutical Co Ltd stock price (4069 JPY) is 33% less than its Relative Value (6 063.36 JPY). Open Relative Valuation
Takeda Pharmaceutical Co Ltd has upside potential of 21% compared to the average analyst price target.
Open Wall St Estimates
Takeda Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 1% per year over the next 3 years.
Takeda Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 3% to 4%.
Takeda Pharmaceutical Co Ltd's short-term assets (2T JPY) exceed its short-term liabilties (2T JPY).
Takeda Pharmaceutical Co Ltd's Revenue has grown by 6% over the past 12 months.
Takeda Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Takeda Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Takeda Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 8% to 3%.
Takeda Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 4%.
Takeda Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
Takeda Pharmaceutical Co Ltd's Revenue has been growing by 9% per year for the last 3 years.
Takeda Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 5%. The company is efficient at transforming stockholders' equity into net income.
Takeda Pharmaceutical Co Ltd has a very low three-year average ROIC (Return on Invested Capital): 4%. The company is not efficient at using invested capital to generate operating income.
Takeda Pharmaceutical Co Ltd's long-term assets (14T JPY) exceed its long-term liabilties (7T JPY).
Takeda Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.64.
Takeda Pharmaceutical Co Ltd has negative Free Cash Flow for the last twelve months.
Takeda Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Takeda Pharmaceutical Co Ltd's Altman Z-Score is very low and is equal to 1.03.
Takeda Pharmaceutical Co Ltd has positive Net Debt. This means that the company has more debt (4T JPY) than cash and short-term investments (317B JPY).
Takeda Pharmaceutical Co Ltd generates enough operating income (465B JPY) to cover interest payments on its debt (101B JPY).
Valuation Backtest
Takeda Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Takeda Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Takeda Pharmaceutical Co Ltd
Balance Sheet Decomposition
Takeda Pharmaceutical Co Ltd
| Current Assets | 2.4T |
| Cash & Short-Term Investments | 317.4B |
| Receivables | 743.1B |
| Other Current Assets | 1.4T |
| Non-Current Assets | 11.8T |
| Long-Term Investments | 372.9B |
| PP&E | 1.8T |
| Intangibles | 9.2T |
| Other Non-Current Assets | 371.4B |
| Current Liabilities | 2.3T |
| Accounts Payable | 483.7B |
| Other Current Liabilities | 1.8T |
| Non-Current Liabilities | 5.2T |
| Long-Term Debt | 4.3T |
| Other Non-Current Liabilities | 905B |
Earnings Waterfall
Takeda Pharmaceutical Co Ltd
|
Revenue
|
4.2T
JPY
|
|
Cost of Revenue
|
-1.4T
JPY
|
|
Gross Profit
|
2.8T
JPY
|
|
Operating Expenses
|
-2.4T
JPY
|
|
Operating Income
|
464.9B
JPY
|
|
Other Expenses
|
-286.7B
JPY
|
|
Net Income
|
178.2B
JPY
|
Free Cash Flow Analysis
Takeda Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Takeda Pharmaceutical Co Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Takeda Pharmaceutical Co Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Takeda Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Takeda Pharmaceutical Co Ltd
is 4 916.4 JPY
with a low forecast of 4 242 JPY and a high forecast of 6 090 JPY.
Shareholder Return
Price
Takeda Pharmaceutical Co Ltd
| Average Annual Return | 5.39% |
| Standard Deviation of Annual Returns | 19.34% |
| Max Drawdown | -36% |
| Market Capitalization | 6.4T JPY |
| Shares Outstanding | 1 585 118 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Takeda Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,347 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
Takeda Pharmaceutical Co Ltd
stock under the Base Case scenario is
5 133.2
JPY.
Compared to the current market price of 4 069 JPY,
Takeda Pharmaceutical Co Ltd
is
Undervalued by 21%.
You don't have any saved screeners yet
